Scilex Holding (SCLX) Return on Capital Employed (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Return on Capital Employed of 203.13% for Q1 2026, up 15475.0% year-over-year from N/an in Q1 2025, and down 4.18% on a QoQ basis from 211.99% in Q4 2025.
Scilex Holding (SCLX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Return on Capital Employed for 6 consecutive years, with 203.13% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 15475.0% year-over-year to 203.13%; the TTM figure through Mar 2026 stood at 203.13% (up 15475.0% YoY), while the FY2025 annual figure was 135.86%, up 8454.0% from the prior year.
- Return on Capital Employed came in at 203.13% for Q1 2026 at Scilex Holding, down from 211.99% in the prior quarter.
- The five-year high for Return on Capital Employed was 211.99% in Q4 2025, with the low at 2940.51% in Q2 2023.
- Average Return on Capital Employed over 5 years is 145.26%, with a median of 48.38% recorded in 2025.
- Across the five-year window, Return on Capital Employed sank 290096 bps in 2023 and surged 299906 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 103.02% in 2022, then surged by 164 bps to 66.12% in 2023, then retreated by 23 bps to 51.18% in 2024, then jumped by 314 bps to 211.99% in 2025, then slipped by 4 bps to 203.13% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 203.13%, 211.99%, and 146.98% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 42.94% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 28.18% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 16.47% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.76% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -10.20% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 203.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 203.13% |
| Dec 31, 2025 | 211.99% |
| Sep 30, 2025 | 146.98% |
| Jun 30, 2025 | 43.06% |
| Mar 31, 2025 | 48.38% |
| Dec 31, 2024 | 51.18% |
| Sep 30, 2024 | 40.97% |
| Jun 30, 2024 | 58.55% |
| Mar 31, 2024 | 63.55% |
| Dec 31, 2023 | 66.12% |
| Sep 30, 2023 | 85.41% |
| Jun 30, 2023 | -2,940.51% |
| Mar 31, 2023 | -310.33% |
| Dec 31, 2022 | -103.02% |
| Sep 30, 2022 | -54.61% |
| Jun 30, 2022 | -39.55% |
| Mar 31, 2022 | -40.65% |
| Dec 31, 2021 | 59.11% |
| Sep 30, 2021 | -0.45% |
| Jun 30, 2021 | -0.25% |